Trials / Completed
CompletedNCT00760981
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- David Miklos · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine if subjects with steroid refractory cGVHD can tolerate imatinib mesylate and whether their cGVHD responds to imatinib mesylate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib | The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily. |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2008-09-26
- Last updated
- 2020-04-15
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00760981. Inclusion in this directory is not an endorsement.